C5 and paroxysmal nocturnal hemoglobinuria: C5 blocker eculizumab is the first-in-class complement inhibitor that has been approved for paroxysmal nocturnal hemoglobinuria (PNH), aHUS, myasthenia gravis, and neuromyelitis optica.